Literature DB >> 8628494

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

J Tedroff1, M Pedersen, S M Aquilonius, P Hartvig, G Jacobsson, B Långström.   

Abstract

Changes in striatal binding of [11C]raclopride, a dopamine D2 receptor antagonist, induced by acute levodopa administration, were evaluated with PET in 10 patients with idiopathic Parkinson's disease (PD). The patients were scanned on two occasions: drug-free and 15 minutes after a 5-minute intravenous infusion of 3 mg/kg levodopa. Levodopa administration produced reductions in striatal [11C]raclopride uptake index with a rostrocaudal gradient. The most pronounced reduction was found in the posterior putamen (to 82% of baseline), followed by the anterior putamen (to 88% of baseline) and the caudate nucleus (to 94% of baseline). The magnitude of [11C]raclopride uptake index reduction correlated with drug-free disability. Moreover, in four hemiparkinsonian patients, a reduction in [11C]raclopride uptake index was measured in the putamen contralateral to the parkinsonian symptoms. The present results demonstrate a positive correlation between striatal dopaminergic nerve-terminal deficiency and the capacity for levodopa to increase synaptic dopamine and displace [11C]raclopride binding, which corresponds to an accelerated amine turnover in dopamine-depleted striatal tissue. We therefore suggest that dopaminergic degeneration in PD is paralleled by a progressive acceleration of amine turnover. This mechanistic consequence of nigrostriatal degeneration, the selective restoration of synaptic dopaminergic neurotransmission in denervated striatal subregions, may explain the effectiveness of levodopa in producing symptomatic benefits in early PD. However, we also suggest that in the vastly denervated striatum, as in advanced PD, an excessive acceleration of amine turnover results in swings in levodopa-induced synaptic dopamine levels that are far beyond normal. This phenomenon most likely plays a key role in the pathogenesis underlying the development of motor-response complications in PD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628494     DOI: 10.1212/wnl.46.5.1430

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.

Authors:  Lars M Bjorklund; Rosario Sánchez-Pernaute; Sangmi Chung; Therese Andersson; Iris Yin Ching Chen; Kevin St P McNaught; Anna-Liisa Brownell; Bruce G Jenkins; Claes Wahlestedt; Kwang-Soo Kim; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 3.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

Review 4.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 5.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

Review 6.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 7.  Imaging insights into basal ganglia function, Parkinson's disease, and dystonia.

Authors:  A Jon Stoessl; Stephane Lehericy; Antonio P Strafella
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 9.  Neurocomputational models of basal ganglia function in learning, memory and choice.

Authors:  Michael X Cohen; Michael J Frank
Journal:  Behav Brain Res       Date:  2008-10-04       Impact factor: 3.332

Review 10.  A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications.

Authors:  George E Jaskiw; Anand P Popli
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.